A biosimilar is a biologic that is highly similar to a licensed biologic (the reference product) in terms of purity, safety and efficacy. If the reference product is licensed to treat multiple therapeutic indications, extrapolation of indications, i.e., approval of a biosimilar for use in an indication held by the reference product but not directly studied in a comparative clinical trial with the biosimilar, may be possible but has to be scientifically justified. Here, we describe the data required to establish biosimilarity and emphasize that indication extrapolation is based on scientific principles and known mechanism of action
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare syste...
Biologics are an integral component in the treatment of various diseases. However, limited patient a...
Biosimilars are biologic products that are highly similar to, and have no clinically meaningful diff...
AbstractA biosimilar is a biologic that is highly similar to a licensed biologic (the reference prod...
John RP Tesser,1 Daniel E Furst,2 Ira Jacobs3 1Arizona Arthritis & Rheumatology Associates, Phoe...
AbstractA biosimilar is intended to be highly similar to a reference biologic such that any differen...
Biologic therapies have revolutionized treatment of a number of diseases. Patents and exclusivity fo...
Biological drugs are vital but often high-cost components of cancer treatment. Several biosimilar ve...
Despite availability of biologic therapies, limited patient access to many of the most-effective can...
AbstractBiological agents or “biologics” are widely used in oncology practice for cancer treatment a...
According to PubMed, the term ‘biosimilar’ has existed for 10 years in scientific literature, with t...
BACKGROUND:Biologic drugs have revolutionised the management of many inflammatory conditions. Patent...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
AbstractA biosimilar is an officially regulated and approved copy of an originator biologic therapy....
A biosimilar is a biological medicinal product claimed to be similar to a reference biolog...
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare syste...
Biologics are an integral component in the treatment of various diseases. However, limited patient a...
Biosimilars are biologic products that are highly similar to, and have no clinically meaningful diff...
AbstractA biosimilar is a biologic that is highly similar to a licensed biologic (the reference prod...
John RP Tesser,1 Daniel E Furst,2 Ira Jacobs3 1Arizona Arthritis & Rheumatology Associates, Phoe...
AbstractA biosimilar is intended to be highly similar to a reference biologic such that any differen...
Biologic therapies have revolutionized treatment of a number of diseases. Patents and exclusivity fo...
Biological drugs are vital but often high-cost components of cancer treatment. Several biosimilar ve...
Despite availability of biologic therapies, limited patient access to many of the most-effective can...
AbstractBiological agents or “biologics” are widely used in oncology practice for cancer treatment a...
According to PubMed, the term ‘biosimilar’ has existed for 10 years in scientific literature, with t...
BACKGROUND:Biologic drugs have revolutionised the management of many inflammatory conditions. Patent...
Biosimilars are biological medicinal products marketed as a copy of an originator (reference) produc...
AbstractA biosimilar is an officially regulated and approved copy of an originator biologic therapy....
A biosimilar is a biological medicinal product claimed to be similar to a reference biolog...
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare syste...
Biologics are an integral component in the treatment of various diseases. However, limited patient a...
Biosimilars are biologic products that are highly similar to, and have no clinically meaningful diff...